FEATURED EDITORIAL
Drug Discovery Online's 2025 Top 5 most consequential shifts affecting this rapidly evolving field, including NAMs, AI, Individualized Therapies, Innovating China, and Early-stage Funding Volatility.
- Small Cells, Big Shifts: Recent Advances In Targeting Small Cell Lung Cancer
- CROs In Early Drug Discovery, Part 3: Budgets, Timelines, And Avoiding Pitfalls
- Rats Behind The Wheel: The Right Preclinical Way To Investigate Drug Effects On Driving?
- Biotech Wasn't Ready For AI's Speed; Here's How We Catch Up
- Strained Manufacturing, Complexity Stymie In Vivo Progress
- To Fight Cancer, Gene Editing Needs To Solve Its Delivery Problem
- Is Oncology Precision Medicine Coming of Age?
FEATURED APPLICATION CONTENT
-
Scalable lentiviral vector production is moving beyond adherent systems. Learn how streamlined workflows enable linear scale-up in stirred-tank bioreactors for cost-effective gene therapy manufacturing.
-
Decoding immune cell interactions reveals critical insights for cancer therapy. Advanced imaging and spectral analysis enable precise identification of synapses, accelerating immuno-oncology research.
-
Explore how efficient powder-liquid mixing and sterile filtration preserve media integrity and support reproducibility in biopharmaceutical workflows, with promising scalability for larger-volume applications.
-
Explore how particle levels remained stable during 24 hours of high-speed mixing, even under extreme temperatures, confirming a system’s suitability for final fill and other particulate-sensitive applications.
-
Explore how a modular AAV8 platform enables scalable, GMP-ready gene therapy manufacturing with reproducible outcomes, streamlined tech transfer, and adaptability across serotypes.
-
Discover how a CDMO achieved 40x productivity and 15% cost savings by switching to rapid cycling membrane chromatography for ADC polishing, which helped cut process time and buffer use.
-
Continuous biomanufacturing is reshaping how active pharmaceutical ingredients are produced. Learn how modular, automated virus inactivation solutions are helping manufacturers improve efficiency.
-
Explore how digital tools are advancing peptide purification, with a focus on GLP-1 receptor agonists, as well as how process efficiency can be accelerated through real-time insights.
-
Gain insight into how consolidating downstream operations into a single automated system can reduce footprint, cut processing time, and minimize manual errors to help teams work more efficiently.
-
Explore a scalable AAV production platform that improves full capsid yield and dramatically reduces host cell impurities, offering a practical solution to common manufacturing challenges.
-
Discover scalable strategies for overcoming AAV purification challenges, from low yield and impurity removal to serotype variability, as well as how advanced tools can streamline manufacturing.
-
Process intensification demands smarter orchestration, real-time analytics, and scalable automation. Discover how digital infrastructure enables synchronized, compliant, and predictive biomanufacturing.
- 2025's Top 5 Drug Discovery Highlights And How To Stay Ahead In 2026
- GO‑4 Drug Combo Offers New Hope for Treating Late-Stage BRCA/PALB2-Mutated Cancers
- From Funding Gaps to AI Frontiers: Insights from the Boston Globe Summit 2025
- Live Insights: 45% Believe The NAMs Industry Should Expand Pre-Competitive Data Sharing Programs
- OpenFold3 Released: Redefining The Limits Of Protein Prediction Models
FEATURED NEWS HEADLINES
- ASG Receives U.S. FDA IND Approval To Initiate Phase 1 Clinical Trial Of The Lead Drug Beta1 For Male Erectile Dysfunction
- Recludix Pharma Announces FDA Clearance Of Investigational New Drug Application For REX-8756, An Oral STAT6 Inhibitor, To Enter Into The Clinic
- Immusoft Secures FDA Orphan Drug Designation For ISP-002 In MPS II, A Progressive Lysosomal Storage Disease
- Basilea And Phare Bio Enter Partnership Combining Anti-Infectives Industry Expertise With Unique AI Capabilities For The Development Of A Novel Antibiotic
- Inotiv Partners With VUGENE To Advance AI-Driven Drug Discovery And Bioinformatics Capabilities
- NanOlogy Unveils Drug Development Program For Rare Pediatric Brainstem Tumor
- Lindus Health And Quotient Sciences Partner To Accelerate Drug Development From First-In-Human To Pivotal Trials
- Chemify Receives An Additional Grant To Accelerate Digital Chemistry Small-Molecule Discovery For Tuberculosis
- Ascletis Announces China National Medical Products Administration Acceptance Of New Drug Application For Denifanstat (ASC40), A First-In-Class FASN Inhibitor For Acne Treatment
- Sagimet's License Partner Ascletis Announced Acceptance Of New Drug Application For Denifanstat For The Treatment Of Moderate To Severe Acne By China's National Medical Products Administration
ARCHIVED NEWSLETTER
- 12.16.25 -- Returning To Nature: Discovering The Next Generation Of Medicines
- 12.09.25 -- When Preclinical Models Distort The Patient
- 12.01.25 -- Better Outcomes, Faster: PBPK Modeling For Absorption & Solid Form Security
- 12.01.25 -- Better Outcomes, Faster: PBPK Modeling For Absorption & Solid Form Security
- 11.25.25 -- Answering The Call To Develop Novel Drugs For Rare Diseases